| US 7,579,380 B2 | ||
| Modified release formulations of a bupropion salt | ||
| Werner Oberegger, Mississauga (Canada); Fang Zhou, Davie, Fla. (US); Paul Maes, Toronto (Canada); Stefano Turchetta, Rome (Italy); Graham Jackson, Co. Kildare (Ireland); Pietro Massardo, Rome (Italy); and Mohammad Ashty Saleh, Oakville (Canada) | ||
| Assigned to Biovail Laboratories International S.R.L., St. Michael (Barbados) | ||
| Filed on Jul. 06, 2007, as Appl. No. 11/774,109. | ||
| Application 11/774109 is a continuation of application No. 11/751768, filed on May 22, 2007. | ||
| Application 11/751768 is a continuation of application No. 11/475252, filed on Jun. 27, 2006, granted, now 7,241,805. | ||
| Claims priority of provisional application 60/693906, filed on Jun. 27, 2005. | ||
| Prior Publication US 2008/0038345 A1, Feb. 14, 2008 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/12 (2006.01) | ||
| U.S. Cl. 514—688 | 20 Claims |
| 1. A pharmaceutical composition, comprising:
at least one microparticle comprising at least one core which is surrounded by at least one osmotic subcoat, and at least
one control-releasing coat which surrounds the at least one osmotic subcoat, wherein
said at least one core comprises bupropion hydrobromide and at least one excipient, and said at least one osmotic subcoat
comprises at least one osmotic agent and at least one osmotic deposition vehicle.
|